Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates (Q29620051)
Jump to navigation
Jump to search
scientific article (publication date: July 2010)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates |
scientific article (publication date: July 2010) |
Statements
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates (English)
Brahmer JR
Drake CG
Wollner I
Powderly JD
Picus J
Sharfman WH
Stankevich E
Pons A
Salay TM
McMiller TL
Gilson MM
Wang C
Selby M
Taube JM
Anders R
Chen L
Korman AJ
Pardoll DM
Lowy I
Topalian SL
1 July 2010
28
19
3167-75